Analysts and US policymakers highlighted sweeping changes in China’s clinical‑trial rules that have dramatically shortened timelines for starting human studies, including a 2018 'implied approval' mechanism for INDs. A government advisory commission and industry witnesses said the reforms transformed China from one of the slowest to one of the fastest markets for trial initiation, enabling more domestic and international studies. BIO board member testimony to Congress warned the US about the strategic implications: faster trial starts and decentralized site models may drive investment and talent toward China unless the US reforms regulatory pathways or incentives. The coverage cited NSCEB analysis and direct testimony from industry leaders to Congress.